Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/cdr
Submission Deadline: 31 Jan 2019
Contacts: Elaine Gao, Managing Editor, email@example.com
The following list shows the information of planned papers to this special issue. All the papers submitted to Cancer Drug Resistance will go through a rigorous peer review. (Please note that the information below is provisional and may be subject to future change)
Title: Opportunities and challenges of implementing Pharmacogenomics in Cancer Drug Development
Authors: Paolo Tarantino1,2 and Giuseppe Curigliano1,2
1. Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan
2. Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy3. To whom correspondence should be sent
Abstract: Cancer drug development is a time and resources consuming process. Around 90% of drugs entering clinical trials fail due to lack of efficacy and/or occurrence of serious adverse events, many of which after hugely expensive phase III studies. Part of the discarded drugs might be beneficial only in a subgroup of the study patients, and some adverse events might be prevented by identifying those patients more vulnerable to toxicities. The implementation of pharmacogenomic biomarkers allows such categorization of patients, in order to predict efficacy and toxicity biomarkers and to optimize the drug development process. Around seventy FDA approved drugs currently present one or more genetic biomarker to keep in consideration, and with the progress of Precision Medicine (PM) tailoring therapies on individuals’ genomic landscape promises to become a new standard of cancer care. In the current article we review the role of pharmacogenomics in cancer drug development, underlying the advantages and challenges of its implementation in this setting.
Title: Conquering cancer drug resistance using genomic medicine - the quest for evidence
Authors: Theodoros G. Soldatos, Sajo Kaduthanam, David Jackson
Afiliations: Molecular Health GmbH, Heidelberg, Germany.
Abstract: While the application of genomic technologies to the molecular characterization of patient tumors continues to emerge as a rational and highly promising approach for guiding treatment decisions, conclusive evidence of clinical utility remains wanting. The result is an environment where innovators accrue significant financial burden and risk, whilst patients, providers, payers and regulators await evidence of clinical and pharmacoeconomic benefit. It is therefore incumbent on every exponent of clinical NGS-testing and/or treatment decision support analytics, to expeditiously and cost-effectively demonstrate the positive impact of these technologies on drug resistance/response, patient survival and/or quality of life. Here we review perspectives on the current status of these efforts globally.